{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:01:41Z","timestamp":1792123301949,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32060201"],"award-info":[{"award-number":["32060201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013078","name":"Natural Science Research Project of Guizhou Province","doi-asserted-by":"publisher","award":["ZK [2024] YB 289"],"award-info":[{"award-number":["ZK [2024] YB 289"]}],"id":[{"id":"10.13039\/501100013078","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In the vascular system, angiotensin II (Ang II) mediated vasoconstriction by inducing the production of 20-hydroxyeicosatetraenoic acid (20-HETE). However, the role of 20-HETE in Ang II-induced cardiac dysfunction had yet to be fully elucidated. This study investigated the effects of Ang II on CYP4A expression and 20-HETE production in H9c2 cells using RT-qPCR, Western blot, and ELISA. The role of 20-HETE in Ang II-induced cardiac hypertrophy was examined using DHE, MitoSOX, and JC-1 staining to evaluate reactive oxygen species (ROS) generation and mitochondrial membrane potential changes. The ERK\/Akt and CaN\/NFAT3 signaling pathways were analyzed through Western blot. Ang II was found to promote CYP4A expression and 20-HETE production in H9c2 cells via an AT1 receptor-dependent mechanism. Additionally, the upregulation of AT1 receptor expression by 20-HETE further confirms its facilitatory effect on the Ang II signaling pathway. Inhibition of 20-HETE synthesis or blockade of its receptor, G-protein-coupled receptor 75 (GPR75), significantly reversed Ang II-induced cardiac hypertrophy. This reversal was closely associated with 20-HETE-induced ROS production, oxidative stress, and activation of the Ca\n                    <jats:sup>2+<\/jats:sup>\n                    \/CaN\/NFAT3 signaling pathway. This study demonstrated that 20-HETE mediated Ang II-induced cardiac hypertrophy and, for the first time, highlighted the significant role of the GPR75 receptor in this process. These findings suggested that targeting 20-HETE reduction or blocking its receptor action could offer a novel therapeutic approach for cardiovascular diseases associated with Ang II.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-85992-2","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:28:08Z","timestamp":1737109688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["20-HETE mediates Ang II-induced cardiac hypertrophy via ROS and Ca2+ signaling in H9c2 cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Jingyi","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianlian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"85992_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41569-023-00887-x","volume":"20","author":"J Ritterhoff","year":"2023","unstructured":"Ritterhoff, J. & Tian, R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat. Rev. Cardiol. 20, 812\u2013829 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"85992_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10741-021-10134-5","volume":"27","author":"G Giamouzis","year":"2022","unstructured":"Giamouzis, G., Dimos, A., Xanthopoulos, A., Skoularigis, J. & Triposkiadis, F. Left ventricular hypertrophy and sudden cardiac death. Heart Fail. Rev. 27, 711\u2013724 (2022).","journal-title":"Heart Fail. Rev."},{"key":"85992_CR3","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/ejhf.3076","volume":"25","author":"M Polovina","year":"2023","unstructured":"Polovina, M. et al. Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies. Eur. J. Heart Fail. 25, 2144\u20132163 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"85992_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14728222.2022.2031974","volume":"26","author":"AJ Winkle","year":"2022","unstructured":"Winkle, A. J. et al. Emerging therapeutic targets for cardiac hypertrophy. Expert Opin. Ther. Tar. 26, 29\u201340 (2022).","journal-title":"Expert Opin. Ther. Tar."},{"key":"85992_CR5","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3390\/jcm12216873","volume":"12","author":"I Caputo","year":"2023","unstructured":"Caputo, I., Bertoldi, G., Driussi, G., Cacciapuoti, M. & Cal\u00f2, L. A. The RAAS goodfellas in cardiovascular system. J. Clin. Med. 12, 6873 (2023).","journal-title":"J. Clin. Med."},{"key":"85992_CR6","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/cells11213336","volume":"11","author":"SK Bhullar","year":"2022","unstructured":"Bhullar, S. K. & Dhalla, N. S. Angiotensin II-Induced Signal Transduction mechanisms for Cardiac Hypertrophy. Cells-basel 11, 3336 (2022).","journal-title":"Cells-basel"},{"key":"85992_CR7","unstructured":"Mancia, G. et al. ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: Endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 41, 1874\u20132071 (2023)."},{"key":"85992_CR8","doi-asserted-by":"publisher","first-page":"e10865","DOI":"10.15252\/emmm.201910865","volume":"12","author":"M Sweeney","year":"2020","unstructured":"Sweeney, M., Corden, B. & Cook, S. A. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol. Med. 12, e10865 (2020).","journal-title":"EMBO Mol. Med."},{"key":"85992_CR9","first-page":"15","volume":"136","author":"NL Plenty","year":"2018","unstructured":"Plenty, N. L. et al. Arachidonic acid metabolites of CYP4A and CYP4F are altered in women with preeclampsia. Prostag Oth Lipid M 136, 15\u201322 (2018).","journal-title":"Prostag Oth Lipid M"},{"key":"85992_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2174\/15680266113139990110","volume":"13","author":"KZ Edson","year":"2013","unstructured":"Edson, K. Z. & Rettie, A. E. CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid \u03c9-hydroxylase activities. Curr. Top. Med. Chem. 13, 1429\u20131440 (2013).","journal-title":"Curr. Top. Med. Chem."},{"key":"85992_CR11","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.bcp.2008.03.004","volume":"75","author":"JP Hardwick","year":"2008","unstructured":"Hardwick, J. P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol. 75, 2263\u20132275 (2008).","journal-title":"Biochem. Pharmacol."},{"key":"85992_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/HYPERTENSIONAHA.118.10269","volume":"72","author":"RJ Roman","year":"2018","unstructured":"Roman, R. J. & Fan, F. 20-HETE: Hypertension and Beyond. Hypertension 72, 12\u201318 (2018).","journal-title":"Hypertension"},{"key":"85992_CR13","doi-asserted-by":"crossref","unstructured":"Pascale, J. V. et al. 20-Hydroxyeicosatetraenoic acid (20-HETE): bioactions, receptors, vascular function, cardiometabolic disease and beyond. In Advances in Pharmacology vol. 97 229\u2013255 (Elsevier, 2023).","DOI":"10.1016\/bs.apha.2023.01.002"},{"key":"85992_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/abio.2001.5044","volume":"292","author":"K Nithipatikom","year":"2001","unstructured":"Nithipatikom, K. et al. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal. Biochem. 292, 115\u2013124 (2001).","journal-title":"Anal. Biochem."},{"key":"85992_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pharmthera.2018.07.004","volume":"192","author":"P Rocic","year":"2018","unstructured":"Rocic, P. & Schwartzman, M. L. 20-HETE in the regulation of vascular and cardiac function. Pharmacol. Therapeut. 192, 74\u201387 (2018).","journal-title":"Pharmacol. Therapeut."},{"key":"85992_CR16","doi-asserted-by":"publisher","first-page":"H1109","DOI":"10.1152\/ajpheart.00067.2010","volume":"299","author":"Q Zeng","year":"2010","unstructured":"Zeng, Q. et al. 20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type ca 2+ channel via a PKC-dependent mechanism in cardiomyocytes. Am. J. Physiol-Heart C. 299, H1109\u2013H1117 (2010).","journal-title":"Am. J. Physiol-Heart C"},{"key":"85992_CR17","first-page":"294","volume":"57","author":"Y Bao","year":"2011","unstructured":"Bao, Y. et al. 20-HETE induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways. J. Cardiovasc. Pharmacol. 57, 294\u2013301 (2011).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"85992_CR18","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1253\/circj.CJ-12-1211","volume":"77","author":"Y Han","year":"2013","unstructured":"Han, Y. et al. 20-Hydroxyeicosatetraenoic acid mediates isolated heart ischemia\/reperfusion injury by increasing NADPH oxidase-derived reactive oxygen species production. Circ. J. 77, 1807\u20131816 (2013).","journal-title":"Circ. J."},{"key":"85992_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1124\/dmd.115.063776","volume":"43","author":"HN Althurwi","year":"2015","unstructured":"Althurwi, H. N., Maayah, Z. H., Elshenawy, O. H. & El-Kadi, A. O. S. Early changes in cytochrome P450s and their associated arachidonic acid metabolites play a crucial role in the initiation of cardiac hypertrophy induced by isoproterenol. Drug Metab. Dispos. 43, 1254\u20131266 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"85992_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/FJC.0b013e3182055baf","volume":"57","author":"ME Aboutabl","year":"2011","unstructured":"Aboutabl, M. E., Zordoky, B. N. M., Hammock, B. D. & El-Kadi, A. O. S. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by Benzo(a)pyrene. J. Cardiovasc. Pharm. 57, 273 (2011).","journal-title":"J. Cardiovasc. Pharm."},{"key":"85992_CR21","doi-asserted-by":"publisher","first-page":"e82482","DOI":"10.1371\/journal.pone.0082482","volume":"8","author":"F Fan","year":"2013","unstructured":"Fan, F. et al. 20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K\u2009+\u2009Channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels. PLoS ONE 8, e82482 (2013).","journal-title":"PLoS ONE"},{"key":"85992_CR22","doi-asserted-by":"publisher","first-page":"F544","DOI":"10.1152\/ajprenal.2000.279.3.F544","volume":"279","author":"KD Croft","year":"2000","unstructured":"Croft, K. D., McGiff, J. C., Sanchez-Mendoza, A. & Carroll, M. A. Angiotensin II releases 20-HETE from rat renal microvessels. Am. J. Physiol. Ren. Physiol. 279, F544\u2013551 (2000).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"85992_CR23","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1152\/ajpregu.00664.2001","volume":"283","author":"M Alonso-Galicia","year":"2002","unstructured":"Alonso-Galicia, M., Maier, K. G., Greene, A. S., Cowley, A. W. & Roman, R. J. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R60\u201368 (2002).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"85992_CR24","doi-asserted-by":"publisher","first-page":"H1194","DOI":"10.1152\/ajpheart.00733.2010","volume":"300","author":"IJ Tsai","year":"2011","unstructured":"Tsai, I. J., Croft, K. D., Puddey, I. B., Beilin, L. J. & Barden, A. 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am. J. Physiol. Heart Circ. Physiol. 300, H1194\u20131200 (2011).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"85992_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FJC.0000000000000248","volume":"66","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. 20-Hydroxyeicosatetraenoic acid is a key mediator of angiotensin II\u2013induced apoptosis in cardiac myocytes. J. Cardiovasc. Pharm. 66, 86\u201395 (2015).","journal-title":"J. Cardiovasc. Pharm."},{"key":"85992_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3892\/etm.2014.1598","volume":"7","author":"H Zhou","year":"2014","unstructured":"Zhou, H. et al. Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Exp. Ther. Med. 7, 1116\u20131122 (2014).","journal-title":"Exp. Ther. Med."},{"key":"85992_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000099200","volume":"19","author":"DE Stec","year":"2007","unstructured":"Stec, D. E., Gannon, K. P., Beaird, J. S. & Drummond, H. A. 20-Hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell. Physiol. Biochem. 19, 121\u2013128 (2007).","journal-title":"Cell. Physiol. Biochem."},{"key":"85992_CR28","doi-asserted-by":"publisher","first-page":"158573","DOI":"10.1016\/j.bbalip.2019.158573","volume":"1865","author":"S C\u00e1rdenas","year":"2020","unstructured":"C\u00e1rdenas, S. et al. GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1865, 158573 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"85992_CR29","first-page":"147032032094985","volume":"21","author":"A Piotrowska","year":"2020","unstructured":"Piotrowska, A., Chmielewska, M., Andrzejewski, W., Dziegiel, P. & Podhorska-Okolow, M. Influence of angiotensin II on cell viability and apoptosis in rat renal proximal tubular epithelial cells in in vitro studies. J. Renin-angio-aldo S. 21, 1470320320949850 (2020).","journal-title":"J. Renin-angio-aldo S"},{"key":"85992_CR30","doi-asserted-by":"publisher","first-page":"116042","DOI":"10.1016\/j.biopha.2023.116042","volume":"170","author":"J Liao","year":"2024","unstructured":"Liao, J. et al. Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells. Biomed. Pharmacother. 170, 116042 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"85992_CR31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/01.HYP.0000168051.04275.ea","volume":"45","author":"FA Yaghini","year":"2005","unstructured":"Yaghini, F. A. et al. Contribution of arachidonic acid metabolites derived via cytochrome P4504A to angiotensin II-induced neointimal growth. Hypertension 45, 1182\u20131187 (2005).","journal-title":"Hypertension"},{"key":"85992_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.freeradbiomed.2021.02.040","volume":"166","author":"CJA Ramachandra","year":"2021","unstructured":"Ramachandra, C. J. A. et al. Oxidative stress in cardiac hypertrophy: from molecular mechanisms to novel therapeutic targets. Free Radical Bio Med. 166, 297\u2013312 (2021).","journal-title":"Free Radical Bio Med."},{"key":"85992_CR33","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/antiox11091822","volume":"11","author":"JP Teuber","year":"2022","unstructured":"Teuber, J. P., Essandoh, K., Hummel, S. L., Madamanchi, N. R. & Brody, M. J. NADPH oxidases in diastolic dysfunction and heart failure with preserved ejection fraction. Antioxidants (Basel) 11, 1822 (2022).","journal-title":"Antioxidants (Basel)"},{"key":"85992_CR34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/CIRCULATIONAHA.114.011079","volume":"131","author":"QD Zhao","year":"2015","unstructured":"Zhao, Q. D. et al. NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt\/mTOR and NF\u03baB signaling pathways. Circulation 131, 643\u2013655 (2015).","journal-title":"Circulation"},{"key":"85992_CR35","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.3390\/ijms23147587","volume":"23","author":"J Xin","year":"2022","unstructured":"Xin, J. et al. Caveolin-1 alleviates acetaminophen-induced hepatotoxicity in alcoholic fatty liver disease by regulating the Ang II\/EGFR\/ERK axis. Int. J. Mol. Sci. 23, 7587 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"85992_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2174\/1570161111311040013","volume":"11","author":"AM G\u00f3mez","year":"2013","unstructured":"G\u00f3mez, A. M., Ruiz-Hurtado, G., Benitah, J. P. & Dom\u00ednguez-Rodr\u00edguez, A. Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy. Curr. Vasc Pharmacol. 11, 497\u2013506 (2013).","journal-title":"Curr. Vasc Pharmacol."},{"key":"85992_CR37","first-page":"3833","volume":"96","author":"JD Molkentin","year":"1997","unstructured":"Molkentin, J. D. & Olson, E. N. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation 96, 3833\u20133835 (1997).","journal-title":"Circulation"},{"key":"85992_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0092-8674(00)81573-1","volume":"93","author":"JD Molkentin","year":"1998","unstructured":"Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215\u2013228 (1998).","journal-title":"Cell"},{"key":"85992_CR39","first-page":"74","volume":"26","author":"V Garcia","year":"2017","unstructured":"Garcia, V. & Schwartzman, M. L. Recent developments on the vascular effects of 20-hydroxyeicosatetraenoic acid. Curr. Opin. Nephrol. Hy. 26, 74\u201382 (2017).","journal-title":"Curr. Opin. Nephrol. Hy."},{"key":"85992_CR40","first-page":"80","volume":"139","author":"R Rong","year":"2018","unstructured":"Rong, R. et al. Angiotensin II upregulates CYP4A isoform expression in the rat kidney through angiotensin II type 1 receptor. Prostag Oth Lipid M 139, 80\u201386 (2018).","journal-title":"Prostag Oth Lipid M"},{"key":"85992_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/jpet.115.229377","volume":"356","author":"V Garcia","year":"2016","unstructured":"Garcia, V., Shkolnik, B., Milhau, L., Falck, J. R. & Schwartzman, M. L. 20-HETE activates the transcription of angiotensin-converting enzyme via nuclear factor-\u03baB translocation and promoter binding. J. Pharmacol. Exp. Ther. 356, 525\u2013533 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"85992_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejphar.2018.06.010","volume":"833","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Conflicting roles of 20-HETE in hypertension and renal end organ damage. Eur. J. Pharmacol. 833, 190\u2013200 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"85992_CR43","doi-asserted-by":"publisher","first-page":"e006939","DOI":"10.1161\/CIRCHEARTFAILURE.120.006939","volume":"13","author":"K Wang","year":"2020","unstructured":"Wang, K., Basu, R., Poglitsch, M., Bakal, J. A. & Oudit, G. Y. Elevated angiotensin 1\u20137\/Angiotensin II ratio predicts favorable outcomes in patients with heart failure. Circ. Heart Fail. 13, e006939 (2020).","journal-title":"Circ. Heart Fail."},{"key":"85992_CR44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jcmm.13958","volume":"23","author":"Z Cheng","year":"2019","unstructured":"Cheng, Z. et al. Cardiac-specific Mst1 deficiency inhibits ROS-mediated JNK signalling to alleviate Ang II-induced cardiomyocyte apoptosis. J. Cell. Mol. Med. 23, 543\u2013555 (2019).","journal-title":"J. Cell. Mol. Med."},{"key":"85992_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.18433\/J3N318","volume":"18","author":"G Chen","year":"2015","unstructured":"Chen, G. et al. Puerarin suppresses angiotensin II-induced cardiac hypertrophy by inhibiting NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways. J. Pharm. Pharm. Sci. 18, 235\u2013248 (2015).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"85992_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jacc.2011.01.032","volume":"58","author":"C Maack","year":"2011","unstructured":"Maack, C. & B\u00f6hm, M. Targeting mitochondrial oxidative stress in heart failure throttling the afterburner. J. Am. Coll. Cardiol. 58, 83\u201386 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"85992_CR47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00424-020-02505-y","volume":"473","author":"S Hamilton","year":"2021","unstructured":"Hamilton, S., Veress, R., Belevych, A. & Terentyev, D. The role of calcium homeostasis remodeling in inherited cardiac arrhythmia syndromes. Pflug Arch. Eur. J. Phy. 473, 377\u2013387 (2021).","journal-title":"Pflug Arch. Eur. J. Phy."},{"key":"85992_CR48","doi-asserted-by":"publisher","first-page":"L1061","DOI":"10.1152\/ajplung.00096.2005","volume":"289","author":"A Yaghi","year":"2005","unstructured":"Yaghi, A. & Sims, S. M. Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L1061\u20131074 (2005).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"85992_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biochi.2022.01.005","volume":"195","author":"B Murtaza","year":"2022","unstructured":"Murtaza, B., Asghar, F. & Patoli, D. GPR75: an exciting new target in metabolic syndrome and related disorders. Biochimie 195, 19\u201326 (2022).","journal-title":"Biochimie"},{"key":"85992_CR50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/HJH.0000000000003038","volume":"40","author":"K Agostinucci","year":"2022","unstructured":"Agostinucci, K. et al. Blockade of 20-hydroxyeicosatetraenoic acid receptor lowers blood pressure and alters vascular function in mice with smooth muscle-specific overexpression of CYP4A12-20-HETE synthase. J. Hypertens. 40, 498 (2022).","journal-title":"J. Hypertens."},{"key":"85992_CR51","doi-asserted-by":"publisher","first-page":"BSR20171496","DOI":"10.1042\/BSR20171496","volume":"38","author":"L Sedl\u00e1kov\u00e1","year":"2018","unstructured":"Sedl\u00e1kov\u00e1, L. et al. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Bioscience Rep. 38, BSR20171496 (2018).","journal-title":"Bioscience Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85992-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:16:44Z","timestamp":1737112604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85992"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85992-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"17 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2342"}}